Prevention of late lumen loss after coronary angioplasty by photodynamic therapy: Role of activated neutrophils

Molecular and Cellular Biochemistry

Volumn 157, Issue 1-2, 1996, Pages 233-238

  Sluiter, Wim ^a   De Vree, Wil J A ^a   Pietersma, Anneke ^a   Koster, Johan F ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Coronary angioplasty; Intimal hyperplasia; Neutrophil; Photodynamic therapy; Restenosis; Smooth muscle cell

Indexed keywords

AMINOLEVULINIC ACID; BACTERIOCHLORIN; CELL ADHESION MOLECULE; FISH OIL; INTEGRIN; MOLSIDOMINE; PHOTOFRIN; PHOTOSENSITIZING AGENT; PHTHALOCYANINE DERIVATIVE; PROTOPORPHYRIN; PURPURIN DERIVATIVE; SINGLET OXYGEN; TRAPIDIL; VERDIN DERIVATIVE;

ARTERY DIAMETER; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL WALL; CLINICAL TRIAL; CORONARY ARTERY DILATATION; ENDOTHELIUM CELL; HUMAN; LASER; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE; NEUTROPHIL; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOOXIDATION; RESTENOSIS; SIDE EFFECT; SKIN SENSITIZATION;

EID: 0029986114     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00227904     Document Type: Article

References (44)

1. Gruentzig AR, Myler RK, Hanna ES, Turina MI: Transluminal angioplasty of coronary-artery Stenosis [Abstract]. Circulation 56 (suppl II): III-84, 1977
2. Lee PC, Gibbons GH, Dzau VJ: Cellular and molecular mechanisms of coronary artery disease. Coronary Artery Dis 4: 254-259, 1993
3. Forrester JS, Fishbein M, Helfant R, Fagin J: A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 17: 758-769, 1991
4. Serruys PW, Foley DP, Kirkeeide RL, King SB III: Restenosis revisited: insights provided by quantitative coronary angiography. Am Heart J 126: 1243-1267, 1993
5. Wong CS, Leon MB, Popma JJ: New device angioplasty: the impact on restenosis. Coronary Artery Dis 4: 243-253, 1993
6. Jackson CL: Animal models of restenosis. Trends Cardiovasc Med 4: 122-130, 1994
7. Clowes AW, Reidy MA: Prevention of stenosis after vascular reconstruction: pharmacologic control of intimal hyperplasia - A review. J Vasc Surg 13: 885-891, 1991
8. Popma JJ, Califf RM, Topol EJ: Clinical trials of restenosis after coronary angioplasty. Circulation 84: 1426-1436, 1991
9. Faxon DP, Currier JW: Prevention of post-PTCA restenosis. Ann NY Acad Sci 748: 419-427, 1995
10. Wanibuchi H, Dingemans KP, Becker AE, Ueda M, Naruko T, Tanizawa S, Nakamura K: Is the Watanabe Heritable Hyperlipidemic Rabbit a suitable experimental model for percutaneous transluminal coronary angioplasty in humans? A light microscopic, immunohistochemical and ultrastructural study. J Am Coll Cardiol 6: 1490-1496, 1993
11. Kakuta T, Currier JW, Haudenschild CC, Ryan TJ, Faxon DP: Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angioplasty in the hypercholestrolemic rabbit model. Circulation 89: 2809-2815, 1994
12. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ: Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 316: 1371-1375, 1987
13. Zarins CK, Zatina MA, Giddens DP, Ku DN, Glagov S: Shear stress regulation of artery lumen diameter in experimental atherogenesis. J Vasc Surg 5: 413-420, 1987
14. Spears JR, Serur J, Shrophire D, Paulin S: Fluorescence of experimental atheromatous plaques with hematoporphyrin derivative. J Clin Invest 71: 395-399, 1983
15. Figge FHJ, Weiland GS, Manganiello LOJ: Cancer detection and therapy: affinity of neoplastic, embryonic and traumatized tissue for porphyrins and metalloporphyrins. Proc Soc Exp Biol Med 68: 640-641, 1948
16. Litvack F, Grundfest WS, Forrester JS, Fishbein MC, Swan HJC, Corday E, Rider DM, McDermid IS, Pacala TJ, Laudenslager JB: Effects of hematoporphyrin derivative and photodynamic therapy on atherosclerotic rabbits. Am J Cardiol 56: 667-671, 1985
17. Spokojny AM, Serur JR, Skillman J, Spears JR: Uptake of hematoporphyrin derivative by atheromatous plaques: studies in human in vitro and rabbit in vivo. J Am Coll Cardiol 8: 1387-1392, 1986
18. Pollock ME, Eugene J, Hammer-Wilson M, Berns MW: Photosensitization of experimental atheromas by porphyrins. J Am Coll Cardiol 9: 639-646, 1987
19. Ortu P, LaMuraglia GM, Roberts WG, Flotte TJ, Hasan T: Photodynamic therapy of arteries: a novel approach for treatment of experimental intimal hyperplasia. Circulation 85: 1189-1196, 1992
20. Eton D, Colburn MD, Shim V, Panek W, Lee D, Moore WS, Ahn SS: Inhibition of intimal hyperplasia by photodynamic therapy using Photofrin. J Surg Res 53: 558-562, 1992
21. Asahara T, Kato T, Amemiya T, Rakue H, Ooike Y, Shiraishi H, Usiu M, Oda Y, Naito Y, Ibukiyama C: In vivo experimental study on photodynamic therapy for the prevention of restenosis after angioplasty. Circulation 86 (suppl I): 1-846, 1992
22. LaMuraglia GM, ChandraSekar NR, Flotte TJ, Abbott WM, Michaud N, Hasan T: Photodynamic therapy inhibition of experimental intimal hyperplasia: acute and chronic effects. J Vasc Surg 19: 321-331, 1994
23. Nyameke I, Anglin S, McEwan J, MacRobert A, Bown S, Bishop C: Photodynamic therapy of normal and balloon-injured rat carotid arteries using 5-amino-levulinic acid. Circulation 91: 417-425, 1995
24. Dougherty TJ: Photodynamic therapy. Photochem Photobiol 58: 895-900, 1993
25. Foote CS: Definition of Type I and Type II photosensitized oxidation. Photochem Photobiol 54: 659, 1991
26. Gomer GJ, Ferrario A, Hayashi N, Rucker N, Szirth BC, Murphree AL: Molecular, cellular, and tissue responses following photodynamic therapy. Lasers Surg Med 8: 450-463, 1988
27. Okunaka T, Eckhauser ML, Kato H, Bomaminio A, Yamamoto H, Aizawa K, Sarasua MM, Koehler KA: Correlation between photodynamic efficacy of differing porphyrins and membrane partitioning behavior. Lasers Surg Med 12: 98-103, 1992
28. Kreimer-Birnbaum M: Modified porphyrins, chlorins, phthalocyanins, and purpurins: second-generation photosensitizers for photodynamic therapy. Sem Hematol 26: 157-173, 1989
29. Gomer CJ: Preclinical examination of first and second generation photosensitizers used in photodynamic therapy. Photochem Photobiol 54: 1093-1107, 1991
30. Spikes JD: Effects of photodynamic treatment on the thermal-mechanical properties of collagen (rat tail tendon). Photochem Photobiol 57 (suppl): 96S, 1993
31. Dartsch PC, Wunderlich K, Ben-Hur E: Aluminium phthalocyanines-induced photolysis of human vascular wall cells in culture and the effect of fluoride on photodynamic action. Coronary Artery Dis 5: 851-855, 1994
32. Fingar VH, Wieman TJ, Wiehle SA, Cerrito PB: The role of microvascular damage in photodynamic therapy: the effect of treatment on vessel constriction, permeability, and leucocyte adhesion. Cancer Res 52: 1914-1921, 1992
33. deVree WJA, Fontijne-Dorsman ANRD, Koster JF, Sluiter W: Photodynamic treatment of human endothelial cells promotes the adherence of neutrophils in vitro. Br J Cancer: in press, 1996
34. Gilissen MJ, van de Merbel-de Wit LEA, Star WM, Koster JF, Sluiter W: Effect of photodynamic therapy on the endothelial-dependent relaxation of isolated rat aortas. Cancer Res 53: 2548-2552, 1993
35. Zimmerman GA, Prescott SM, McIntyre TM: Endothelial cell interactions with granulocytes: tethering and signalling molecules. Immunol Today 13: 93-100, 1992
36. Foster TH, Primavera MC, Marder VJ, Hilf R, Sporn LA: Photosensitized release of von Willebrand factor from cultured human endothelial cells. Cancer Res 51: 3261-3266, 1991
37. Hattori R, Hamilton KK, McEver RP, Sims PJ: Complement proteins C5b-9 induce secretion of high molecular weight multimer of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 264: 9053-9060, 1989
38. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK: A cascade model for restenosis. A special case of atherosclerosis progression. Circulation 86(suppl III): III47-III52, 1992
39. Hansen PR: Role of neutrophils in myocardial ischemia and reperfusion. Circulation 91: 1872-1885, 1995
40. Pietersma A, Kofflard M, De Wit LEA, Stijnen Th, Koster JF, Serruys PW, Sluiter W: Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. Circulation 91: 1320-1325, 1995
41. Santamaria P, Gehrz RC, Bryan MK, Barbosa JJ: Involvement of class II MHC molecules in the LPS-induction of IL-1/TNF secretions by human monocytes: quantitative differences at the polymorphic level. J Immunol 143: 913-922, 1989
42. Hayes MP, Zoon KC: Priming of human monocytes for enhanced lipopolysaccharide responses: expression of alpha interferon, interferon gamma, and tumor necrosis factor. Infect Immun 61: 3222-3227, 1993
43. Kuijpers TW, Hoogerwerf M, van der Laan LJ, Nagel G, van der School CE, Grunert F, Roos D: CD66 nonspecific cross-reacting antigens are involved in neutrophil adherence to cytokine-activated endothelial cells. J Cell Biol 118: 457-466, 1992
44. Buchanan MR: Inhibition of thrombosis by leukocytes: role of endogenous fatty acid metabolites. Sanofi Foundation Thromb Res Bull 4: 14-22, 1989